Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167262 | 1.00 | PRCP (0.59) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL6066100 | 0.83 | HTR1A (0.40) | PRCPSLC22A1ALDH1A1KDM4EMAPT | |
| SCHEMBL28763197 | 0.82 | PRCP (0.58) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL1717271 | 0.81 | PRCP (0.65) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL6673115 | 0.81 | PRCP (0.56) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL3805979 | 0.79 | PRCP (0.51) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL13977536 | 0.79 | PRCP (0.67) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL12878929 | 0.78 | OPRM1 (0.42) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL4340396 | 0.78 | PRCP (0.61) | PRCPSLC22A1OPRM1GAAALDH1A1 | |
| SCHEMBL23285173 | 0.77 | PRCP (0.53) | PRCPSLC22A1GAASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106831714-A | A kind of tetrahydro isoquinoline compound and its production and use | 南阳师范学院 | 2017-06-13 | — | — | CN | claimed |
| US-20030199534-A1 | Di-substituted pyrimidine compound for treating or modulating disease in which phosphoryl transferase, including kinases may be involved | AMGEN INC. | 2003-10-23 | — | — | US | claimed |
| US-5272270-A | Process for the preparation of 1-alkylisoquinoline derivatives | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1993-12-21 | — | — | US | claimed |
| JP-3148222-A | — | — | None | — | — | JP | disclosed |
| JP-6107639-A | — | — | None | — | — | JP | disclosed |
| CN-115650824-B | Chiral diol and preparation method thereof, prepared catalyst and preparation method and application thereof | 合肥工业大学 | 2024-01-23 | — | — | CN | disclosed |
| US-20230331667-A1 | PROCESS FOR MAKING A PHARMACEUTICAL COMPOUND | ADEPTIO PHARMACEUTICALS LIMITED (GB) | 2023-10-19 | — | — | US | disclosed |
| EP-4261208-A1 | A PROCESS FOR MAKING (+)-ALPHA-DIHYDROBENAZINE | Adeptio Pharmaceuticals Limited (GB) | 2023-10-18 | — | — | EP | disclosed |
| CN-115650824-A | Chiral diol and preparation method thereof, prepared catalyst, preparation method and application | 合肥工业大学 | 2023-01-31 | — | — | CN | disclosed |
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | GOSSAMER BIO SERVICES INC (US) | 2021-05-13 | — | — | US | disclosed |
| CN-106831714-B | A kind of tetrahydro isoquinoline compound and its preparation method and application | 南阳师范学院 | 2019-05-17 | — | — | CN | disclosed |
| WO-2000032656-A2 | POLYMERS CONTAINING SPIROBICYCLIC AMMONIUM MOIETIES AND USE THEREOF | GELTEX PHARMACEUTICALS, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| JP-H06107639-A | PREPARATION OF 1-ALKYLISOQUINOLINE DERIVATIVE | CONSORTIUM ELEKTROCHEM IND GMBH | 1994-04-19 | — | — | JP | disclosed |
| US-5272270-A | Process for the preparation of 1-alkylisoquinoline derivatives | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1993-12-21 | — | — | US | disclosed |
| US-5272270-A | Process for the preparation of 1-alkylisoquinoline derivatives | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1993-12-21 | — | — | US | disclosed |
| EP-0471303-A1 | Process for the preparation of 1-alkylisoquinoline derivatives | Consortium für elektrochemische Industrie GmbH (DE) | 1992-02-19 | — | — | EP | disclosed |
| JP-H03148222-A | PREVENTING AND REMEDY FOR PERKINSONISM | TANABE SEIYAKU CO LTD | 1991-06-25 | — | — | JP | disclosed |
| EP-0040990-B1 | ANTIALLERGIC IMIDODISULFAMIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-01 | — | — | EP | disclosed |
| US-4317826-A | TREATING ASTHMA | SMITHKLINE CORPORATION (US) | 1982-03-02 | — | — | US | disclosed |
| EP-0040990-A1 | Antiallergic imidodisulfamides, their preparation and pharmaceutical compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1981-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199534-A1 | Di-substituted pyrimidine compound for treating or modulating disease in which phosphoryl transferase, including kinases may be involved | DTYMK, PHKG1, TK1 | PRCP 1632/4885SLC22A1 3824/4885OPRM1 4774/4885 |
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ULK1, PHKG2, PHKG1 | PRCP 1206/4885SLC22A1 4449/4885OPRM1 1516/4885 |
| US-20230331667-A1 | PROCESS FOR MAKING A PHARMACEUTICAL COMPOUND | DHPS, CYP3A5, SQLE | PRCP 378/4885SLC22A1 4649/4885OPRM1 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.